HRP20070241T3 - Azabiciklički heterocikli kao modulatori kanabinoid receptora - Google Patents

Azabiciklički heterocikli kao modulatori kanabinoid receptora

Info

Publication number
HRP20070241T3
HRP20070241T3 HR20070241T HRP20070241T HRP20070241T3 HR P20070241 T3 HRP20070241 T3 HR P20070241T3 HR 20070241 T HR20070241 T HR 20070241T HR P20070241 T HRP20070241 T HR P20070241T HR P20070241 T3 HRP20070241 T3 HR P20070241T3
Authority
HR
Croatia
Prior art keywords
group
cycloalkylalkyl
arylalkyl
cycloalkyl
alkyl
Prior art date
Application number
HR20070241T
Other languages
English (en)
Inventor
Yu Guixue
R. Ewing William
B. Mikkilineni Amarendra
Pendri Annapurna
M. Sher Philip
Gerritz Samuel
A. Ellsworth Bruce
Wu Gang
Huang Yanting
Sun Chongqing
Murugesan Natesan
Gu Zhengxiang
Wang Ying
Sitkoff Doree
R. Johnson Stephen
Wu Ximao
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20070241T3 publication Critical patent/HRP20070241T3/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

Spoj formule Iuključujući farmaceutski prihvatljive soli i stereoizomere, naznačen time, da je: n jednostruka veza ili dvostruka veza, R1 je izabran iz skupine koja se sastoji od halogen, cijano, alkil, alkenil, alkinil, cikloalkil, cikloalkilalkil,heterociklil, heterociklilalkil, aril, arilalkil,heteroaril, heteroarilalkil, ariloksi, heteroariloksi, -NR8R9, -CO2R8, CONR8R9, -OR8, -NR8COR9, -NR8CONR8R9, -NR8CO2R9, -OCONR8R9, NR8S(O)mR9, -NR8S(O)mR8R9, -NR8S(O)mOR9 i -OS(O)mNR8R9;R2 je izabraniz skupine koja se sastoji od halogen, cijano, alkil, alkenil, alkinil, cikloalkil, cikloalkilalkil, heterociklil, heterociklilalkil, aril, arilalkil, heteroaril, heteroarilalkil, ariloksi, heteroariloksi, -NR8R9, -CO2R8, CONR8R9, -OR8, -NR8COR8, -NR8CONR8R9, -NR8CO2R9, -OCONR8R9, NR8S(O)mR9, -NR8S(O)mR8R9, -NR8S(O)mOR9 i -OS(O)mNR8R9;R3 je izabran iz skupine koja se sastoji od alkil, alkenil, alkinil, cikloalkil, cikloalkilalkil, heterociklilalkil, arilalkil i heteroarilalkila; R6 je izabran iz skupine koja se sastoji od H, alkil, cikloalkil,heterociklil, cikloalkilalkil, heterocikloalkil, aril, heteroaril, arilalkil i heteroarilalkila, gdje R6 skupina ima molekularnu masu manju od 200 atomskih jedinica mase; R7 je odsutan kada je n dvostruka veza; R7 je izabran iz skupine koja se sastoji od H, alkil, cikloalkil, heterociklil, cikloalkilalkil, heterocikloalkil, aril, heteroaril, arilalkil, heteroarilalkil, -COR8, -CO2R8, -CONR8R9 i -S(O)mR8 kada je n jednostruka veza; R8 i R9 su neovisno izabrani iz skupine koja se sastoji od H, alkil, aril, arilalkil, cikloalkil, cikloalkilalkil,heterociklil, heterocikloalkil, heteroaril i heteroarilalkila, R8 i R9 uzeti zajedno mogu opcijski tvoriti heterociklički prsten od 4, 5, 6 ili 7 članova ili heteroarilni prsten od 5 ili 6 članova; im je cijeli broj koji je 1 ili 2. Patent sadrži još 73 patentna zahtjeva.
HR20070241T 2003-12-19 2007-05-25 Azabiciklički heterocikli kao modulatori kanabinoid receptora HRP20070241T3 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53145103P 2003-12-19 2003-12-19
US11/016,135 US7378418B2 (en) 2003-12-19 2004-12-17 Azabicyclic heterocycles as cannabinoid receptor modulators
PCT/US2004/042820 WO2005063761A1 (en) 2003-12-19 2004-12-17 Azabicyclic heterocycles as cannabinoid receptor modulators

Publications (1)

Publication Number Publication Date
HRP20070241T3 true HRP20070241T3 (hr) 2007-07-31

Family

ID=34703659

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20070241T HRP20070241T3 (hr) 2003-12-19 2007-05-25 Azabiciklički heterocikli kao modulatori kanabinoid receptora

Country Status (20)

Country Link
US (1) US7378418B2 (hr)
EP (1) EP1697370B1 (hr)
JP (1) JP2007514768A (hr)
AT (1) ATE360630T1 (hr)
AU (1) AU2004309365A1 (hr)
BR (1) BRPI0417771A (hr)
CA (1) CA2550435A1 (hr)
CY (1) CY1106674T1 (hr)
DE (1) DE602004006165T2 (hr)
DK (1) DK1697370T3 (hr)
ES (1) ES2282927T3 (hr)
HK (1) HK1095139A1 (hr)
HR (1) HRP20070241T3 (hr)
IL (1) IL176107A0 (hr)
IS (1) IS8502A (hr)
NO (1) NO20062704L (hr)
PL (1) PL1697370T3 (hr)
PT (1) PT1697370E (hr)
RU (1) RU2006126122A (hr)
WO (1) WO2005063761A1 (hr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210590A1 (en) * 1995-09-27 2010-08-19 Northwestern University Compositions and treatments for seizure-related disorders
EP1430033A4 (en) 2001-08-31 2004-12-15 Univ Northwestern PROTEIN KINASE ANTI-INFLAMMATORY AND INHIBITOR COMPOSITION AND METHOD OF USE
JP2007510649A (ja) * 2003-11-04 2007-04-26 メルク　エンド　カムパニー　インコーポレーテッド 置換ナフチリジノン誘導体
MX2007005247A (es) 2004-11-02 2008-03-13 Univ Northwestern Compuestos de piridazina, composiciones y metodos.
CA2589102C (en) 2004-11-02 2013-08-13 Northwestern University Pyridazine compounds and methods for using the compounds to treat inflammatory diseases
BRPI0609614A2 (pt) * 2005-04-04 2010-04-20 Univ Pontificia Catolica Chile uso de ezetimiba na prevenção e tratamento de litìases de colesterol na árvore biliar
US7632837B2 (en) * 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7452892B2 (en) * 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US8022073B2 (en) * 2005-12-07 2011-09-20 Sumitomo Chemical Company, Limited Substituted pyridazine compounds and fungicidal uses thereof
EP1966183A4 (en) * 2005-12-20 2010-12-29 Merck Frosst Canada Ltd HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A-DELTA-9-DESATURASE
AU2007222069A1 (en) * 2006-02-21 2007-09-13 Ampla Pharmaceuticals Inc. CB1 antagonists and inverse agonists
US20090325973A1 (en) 2006-04-28 2009-12-31 Watterson D Martin Formulations containing pyridazine compounds
US8158627B2 (en) * 2006-04-28 2012-04-17 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
AR061637A1 (es) * 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
ATE538095T1 (de) * 2006-11-30 2012-01-15 Dow Agrosciences Llc Verfahren zur herstellung von 2-substituierten 5- (1-alkylthio)-alkylpyridinen
EP1974608A1 (de) * 2007-03-30 2008-10-01 Bayer CropScience AG Arylpyridazine als Fungizide
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
KR101622403B1 (ko) * 2007-04-11 2016-05-31 오메로스 코포레이션 중독의 예방 및 치료용 조성물 및 방법
EA201000046A1 (ru) * 2007-06-21 2011-02-28 Кара Терапеутикс, Инк. Замещенные имидазогетероциклы
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2200997B9 (en) 2007-09-13 2016-01-13 Concert Pharmaceuticals Inc. Synthesis of deuterated benzodioxoles
EP2042491A1 (de) * 2007-09-14 2009-04-01 Bayer CropScience AG Pyridazine als Fungizide
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
CN101590239B (zh) * 2008-05-30 2013-03-27 北京奥萨医药研究中心有限公司 含有利尿剂、他汀和叶酸的药物组合物及其用途
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
AR073010A1 (es) * 2008-08-12 2010-10-06 Takeda Pharmaceutical Compuesto amida con actividad agonista del gpr52
US20100113581A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
US20100113603A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
US20100113583A1 (en) * 2008-10-16 2010-05-06 Aronne Louis J Combination therapies for the treatment of obesity
WO2010045563A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
WO2010045522A2 (en) * 2008-10-16 2010-04-22 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
US20100331419A1 (en) * 2009-06-25 2010-12-30 Aronne Louis J Combination Therapies for the Treatment of Obesity
US20100331420A1 (en) * 2009-06-26 2010-12-30 Aronne Louis J Combination Therapies for the Treatment of Obesity
US20100331999A1 (en) * 2009-06-29 2010-12-30 Aronne Louis J Combination Therapies for the Treatment of Obesity
US20110015663A1 (en) * 2009-07-17 2011-01-20 Aronne Louis J Combination Therapies for the Treatment of Obesity
EP2483407A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
WO2011041632A2 (en) * 2009-10-01 2011-04-07 Metabolous Pharmaceuticals, Inc. Combination therapies for the treatment of obesity
TW201124078A (en) 2009-12-22 2011-07-16 Du Pont Fungicidal 2-(bicyclic aryloxy) carboxamides
EP2518054A1 (en) 2009-12-24 2012-10-31 Takeda Pharmaceutical Company Limited Amide compound
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
EP2612669A4 (en) 2010-08-31 2014-05-14 Snu R&Db Foundation USING THE FÖTAL REPROGRAMMING OF A PPAR AGONIST
US8993591B2 (en) * 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
WO2012087372A1 (en) 2010-12-22 2012-06-28 E. I. Du Pont De Nemours And Company Fungicidal 2-(bicyclic aryloxy)carboxamides
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
JP5437525B1 (ja) 2012-12-28 2014-03-12 株式会社ナード研究所 チロシン誘導体およびチロシン誘導体の製造方法
WO2014154606A1 (en) 2013-03-27 2014-10-02 F. Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy
CN106559998B (zh) 2014-07-30 2022-01-25 豪夫迈·罗氏有限公司 预测对hdl升高剂或hdl模拟剂疗法的应答性的遗传标记
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
CN109476699B (zh) 2016-06-02 2021-10-12 艾伯维公司 糖皮质激素受体激动剂及其免疫偶联物
US11584744B2 (en) * 2017-06-23 2023-02-21 University Of Washington Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them
HUE054428T2 (hu) 2017-12-01 2021-09-28 Abbvie Inc Glükokortikoid receptor agonista és annak immunkonjugátumai
EP3806855B1 (en) 2018-06-15 2023-03-01 Pfizer Inc. Glp-1 receptor agonists and uses thereof
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
AU2021287998A1 (en) 2020-06-11 2023-02-02 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994898A (en) 1975-10-16 1976-11-30 E. R. Squibb & Sons, Inc. 1,2,4-Triazolo (4,3-b) pyridazin-3-ones
US4515791A (en) * 1980-06-03 1985-05-07 American Cyanamid Company Substituted phenyl-1,2,4-triazolo[2,3-b]pyridazin-3(2H)ones as anti-asthma agents
JPS61106576A (ja) 1984-10-31 1986-05-24 Nippon Soda Co Ltd トリアゾロピリダジン−３−オン誘導体及び製造方法
EP1120418A4 (en) 1998-10-06 2005-01-26 Annealed pyridazine compounds, a method for their preparation and their use
JP2002205992A (ja) 2000-11-08 2002-07-23 Takeda Chem Ind Ltd 二環式トリアゾロン誘導体およびそれを含有する除草剤
EP1594848A1 (en) 2003-02-19 2005-11-16 Neurogen Corporation Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds

Also Published As

Publication number Publication date
IS8502A (is) 2006-06-08
DK1697370T3 (da) 2007-09-17
JP2007514768A (ja) 2007-06-07
CA2550435A1 (en) 2005-07-14
CY1106674T1 (el) 2012-05-23
IL176107A0 (en) 2006-10-05
EP1697370B1 (en) 2007-04-25
DE602004006165D1 (de) 2007-06-06
US7378418B2 (en) 2008-05-27
PL1697370T3 (pl) 2007-09-28
HK1095139A1 (en) 2007-04-27
AU2004309365A1 (en) 2005-07-14
RU2006126122A (ru) 2008-01-27
EP1697370A1 (en) 2006-09-06
ES2282927T3 (es) 2007-10-16
ATE360630T1 (de) 2007-05-15
DE602004006165T2 (de) 2008-01-17
WO2005063761A1 (en) 2005-07-14
BRPI0417771A (pt) 2007-04-17
NO20062704L (no) 2006-09-05
US20050143381A1 (en) 2005-06-30
PT1697370E (pt) 2007-05-31

Similar Documents

Publication Publication Date Title
HRP20070241T3 (hr) Azabiciklički heterocikli kao modulatori kanabinoid receptora
HRP20070267T3 (hr) Azabiciklički heterocikli kao modulatori kanabinoid receptora
AR047063A1 (es) Heterociclos azabiciclicos como moduladores de receptor canabinoide
NO20051411L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk bruk derav samt intermediater til fremstilling derav
HRP20080541T3 (hr) Piperazinski derivati i njihova upotreba u liječenju neuroloških i psihijatrijskih bolesti
HRP20010573B1 (hr) Triciklički inhibitori poli(adp-riboza) polimeraza
GB0212048D0 (en) Therapeutic agents
RS52865B (en) Phenyl-piperazine Derivatives As Serotonin Resorption Inhibitors
RS51471B (en) BIPHYNYLOXYXIC ACID DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES
NO20025955L (no) 1,2-dihydropyridinforbindelser, fremgangsmåte for fremstilling av de sammeog anvendelse derav
WO2003037862A1 (fr) Derives amide, et medicaments correspondants
EP0040639A4 (en) ISOXAZOLE DERIVATIVES.
AU2352495A (en) Condensed heterocyclic compounds, their production and use as gnrh antagonists
AR049699A1 (es) Derivados de pirimidina
AU1253002A (en) Imidazo-triazine derivatives as ligands for gaba receptors
HRP20080227T3 (hr) Pirolidinski derivati kao ligandi histaminskih receptora
ATE271868T1 (de) Neue cathechole als antimikrobielle mittel
ATE503746T1 (de) Neue imidazolidinderivate
WO2006030211A3 (en) Acyclic sulphonamides
GB0117277D0 (en) Therapeutic agents
WO2008155670A3 (en) Arylamide pyrimidone compounds
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
WO2008006625A3 (en) Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
SE0201937D0 (sv) Therapeutic agents
AR059329A1 (es) Trialquilsilil-indoles, composiciones farmaceuticas y su utilizacion